SEARCH

SEARCH BY CITATION

References

  • 1
    Burrows B. Airways obstructive diseases: pathogenetic mechanisms and natural histories of the disorders. Med Clin North Am 1990; 74:547559.
  • 2
    Braman SS. The global burden of asthma. Chest 2006; 130:4S12S.
  • 3
    Tan WC, Xiang X, Qiu D, Ng TP, Lam SF, Hegele RG. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med 2003; 115:272277.
  • 4
    Mullooly JP, Bridges CB, Thompson WW et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007; 25:846855.
  • 5
    Miller EK, Griffin MR, Edwards KM et al. Influenza burden for children with asthma. Pediatrics 2008; 121:18.
  • 6
    Dombkowski KJ, Davis MM, Cohn LM, Clark SJ. Effect of missed opportunities on influenza vaccination rates among children with asthma. Arch Pediatr Adolesc Med 2006; 160:966971.
  • 7
    Lyn-Cook R, Halm EA, Wisnivesky JP. Determinants of adherence to influenza vaccination among inner-city adults with persistent asthma. Prim Care Respir J 2007; 16:229235.
  • 8
    Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007; 56:154.
  • 9
    Abadoglu O, Mungan D, Pasaoglu G, Celík G, Misirligil Z. Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations. J Asthma 2004; 41:279283.
  • 10
    Bueving HJ, Bernsen RM, De Jongste JC et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004; 169:488493.
  • 11
    Christy C, Aligne CA, Auinger P, Pulcino T, Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. Arch Dis Child 2004; 89:734735.
  • 12
    Ashkenazi S, Vertruyen A, Arístegui J et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870879.
  • 13
    Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685696.
  • 14
    Redding G, Walker RE, Hessel C et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002; 21:4448.
  • 15
    Fleming DM, Crovari P, Wahn U et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860869.
  • 16
    Tsitoura DC, Kim S, Dabbagh K, Berry G, Lewis DB, Umetsu DT. Respiratory infection with influenza A virus interferes the induction of tolerance to aeroallergens. J Immunol 2000; 165:34843491.
  • 17
    Alexandrova GI, Polezhaev FI, Budilovsky GN et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees. Infect Immun 1984; 44:734739.
  • 18
    Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493.
  • 19
    Hierholzer JC, Suggs MT. Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions. Appl Microbiol 1969; 18:816823.
  • 20
    Naĭkhin AN, Donina SA, Kustikova IuG, Katorgina LG, Rudenko LG. Monoclonal immunoenzyme test-system for evaluating secretory immunity to influenza A and B viruses. Vopr Virusol 1997; 42:212216.
  • 21
    Saxena RK, Weissman D, Simpson J, Lewis DM. Murine model of BCG lung infection: dynamics of lymphocyte subpopulations in lung interstitium and tracheal lymph nodes. J Biosci 2002; 27:143153.
  • 22
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:5563.
  • 23
    Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004; 112:352363.
  • 24
    Torres R, Picado C, De Mora F. Use of the mouse to unravel allergic asthma: a review of the pathogenesis of allergic asthma in mouse models and its similarity to the condition in humans. Arch Bronconeumol 2005; 41:141152.
  • 25
    Holt PG, Vines J, Bilyk N. Effect of influenza virus infection on allergic sensitization to inhaled antigen in mice. Int Arch Allergy Appl Immunol 1988; 86:121123.
  • 26
    Lebrec H, Sarlo K, Burleson GR. Effect of influenza virus infection on ovalbumin-specific IgE responses to inhaled antigen in the rat. J Toxicol Environ Health 1996; 27:619630.
  • 27
    Yamamoto N, Suzuki S, Suzuki Y et al. Immune response induced by airway sensitization after influenza A virus infection depends on timing of antigen exposure in mice. J Virol 2001; 75:499505.
  • 28
    Marsland BJ, Scanga CB, Kopf M, Le Gros G. Allergic airway inflammation is exacerbated during acute influenza infection and correlates with increased allergen presentation and recruitment of allergen-specific T-helper type 2 cells. Clin Exp Allergy 2004; 34:12991306.
  • 29
    Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med 2007; 39:440456.
  • 30
    Dahl ME, Dabbagh K, Liggitt D, Kim S, Lewis DB. Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells. Nat Immunol 2004; 5:337343.